-
Categories
-
Pharmaceutical Intermediates
-
Active Pharmaceutical Ingredients
-
Food Additives
- Industrial Coatings
- Agrochemicals
- Dyes and Pigments
- Surfactant
- Flavors and Fragrances
- Chemical Reagents
- Catalyst and Auxiliary
- Natural Products
- Inorganic Chemistry
-
Organic Chemistry
-
Biochemical Engineering
- Analytical Chemistry
-
Cosmetic Ingredient
- Water Treatment Chemical
-
Pharmaceutical Intermediates
Promotion
ECHEMI Mall
Wholesale
Weekly Price
Exhibition
News
-
Trade Service
The National Institute for Health and Care Excellence (NICE) has recommended AstraZeneca and MSD's Koselugo (selumetinib) for use in the UK NHS
child
NF1 is a debilitating genetic disorder with a prevalence of 1 in 4,000 people
Koselugo works by blocking specific enzymes -- mitogen-activated protein kinase kinases 1 and 2 (also known as MEK 1 and MEK2) that are involved in stimulating cell growth
An open-label phase II trial determined the clinical benefit of selumetinib in patients with plexiform neurofibromas
As of March 29, 2019, a total of 34 patients (68%) had confirmed partial responses, of which 28 had durable responses (lasting ≥1 year)
Original source:
Original source:https:// href="https://" target="_blank" rel="noopener">https:// https://
leave a message here